Some reasons why patients take part in cancer clinical trials
DOI:
https://doi.org/10.35509/01239015.186Keywords:
Cancer, Clinical trials, Research Subjects, VolitionAbstract
Background: Cancer clinical trials require the voluntary participation of patients for their adequate development. Not all patients wish to do this, thus affecting their development. In other studies, the most important identified reasons in that influence the decision have been lack of information about study design, randomisation methods, and kind of treatment, use of placebos, toxicity, and side effects of the investigational medicinal product.
Objective: To evaluate the volition to participate in clinical trials, as well as to establish the reasons associated with this in a sample of patients.
Methods: A cross-sectional observational study was conducted on a sample of cancer patients. This included a logistic regression analysis, taking the volition to participate in clinical trials as the dependent variable, along with a group of explanatory variables.
Results: A total of 366 patients were interviewed. Although 84% did not know about clinical trials, 63% were willing to participate. The reasons the remaining percentage gave for declining to participate were fear, lack of information about risks and benefits, rights, and informed consent.
Conclusion: Additional studies are required to identify the reasons associated with participation in cancer clinical trials. Furthermore, strategies are required for improving the information and communication for patients to take part in clinical trials.
Author Biographies
José Alexander Carreno Dueñas Carreño Dueñas, Instituto Nacional de Cancerología
Grupo Área de Investigaciones, Instituto Nacional de Cancerología, Bogotá D. C., Colombia
Yeinnyer Muleth Zabaleta, Instituto Nacional de Cancerología
Grupo de Investigación Clínica, Instituto Nacional de Cancerología, Bogotá D. C., Colombia
Martha Lucía Díaz, Instituto Nacional de Cancerología
Grupo de Investigación Clínica, Instituto Nacional de Cancerología, Bogotá D. C., Colombia
Maria Lourdes Calderón, Instituto Nacional de Cancerología
Grupo de Investigación Clínica, Instituto Nacional de Cancerología, Bogotá D. C., Colombia
Ricardo Sánchez Pedraza, Instituto Nacional de Cancerología
Universidad Nacional de Colombia, Facultad de Medicina, Grupo de Investigación Clínica, Instituto Nacional de Cancerología, Bogotá D. C., Colombia
References
Institute NC. Cancer Clinical Trials [Internet]. 2013 [cited 2013 Jan 15]. Disponible en: http://www.cancer.gov/cancertopics/factsheet/Information/clinical-trials.
Pocock SJ. Clinical Trials: A Practical Approach. New York: Wiley medical publication; 1984. p. p266.
Rosselli D, Eduardo C, Gutiérrez L. Desenlaces clínicos en hematoncología: diez a˜nos de investigaciones en Pubmed. Rev Colomb Cancerol. 2015;19:19-26.
https://doi.org/10.1016/j.rccan.2015.02.002
Sánchez R, Ballesteros M. Medición de la calidad de vida en ensayos clínicos de pacientes con cáncer. Un estudio bibliométrico. Rev Colomb Cancerol. 2009;13:29-34.
https://doi.org/10.1016/S0123-9015(09)70149-0
Organization WH. International Clinical Trials Registry Platform (ICTRP) [Internet]. 2013. Disponible en: International Clinical Trials Registry Platform.(ICTRP).
Kong H, West S. Ethical principles for medical research involving human subjects. Eur J Emerg Med. 2001;8:221-3.
https://doi.org/10.1097/00063110-200109000-00010
Chu SH, Jeong SH, Kim EJ, Park MS, Park K, Nam M, et al. The views of patients and healthy volunteers on participation in clinical trials: an exploratory survey study. Contemp Clin Trials. 2012;33:611-9.
https://doi.org/10.1016/j.cct.2012.02.018
Jenkins V, Farewell D, Batt L, Maughan T, Branston L, Langridge C, et al. The attitudes of 1066 patients with cancer towards participation in randomised clinical trials. Br J Cancer. 2010;103:1801-7.
https://doi.org/10.1038/sj.bjc.6606004
McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA, et al. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials. 2006;7:9.
https://doi.org/10.1186/1745-6215-7-9
Fallow LJ, Jenkins V, Brennan C, Sawtell M, Moynihan C, Souhami RL. Original Paper Attitudes of Patients to Randomised Clinical Trials of Cancer Therapy. Eur J Cancer. 1998;34:1554-9.
https://doi.org/10.1016/S0959-8049(98)00193-2
Fleissig a, Jenkins V, Fallowfield L. Results of an intervention study to improve communication about randomised clinical trials of cancer therapy. Eur J Cancer [Internet]. 2001 Feb;37(3):322-31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11239753.
https://doi.org/10.1016/S0959-8049(00)00415-9
Zwarenstein M. Pragmatic'' and «explanatory» attitudes to randomised trials. J R Soc Med. 2017;110:208-18.
https://doi.org/10.1177/0141076817706303
Jenkins V, Fallowfield L. Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy. Br J Cancer. 2000;82:1783-8.
https://doi.org/10.1054/bjoc.2000.1142
Llewellyn-Thomas HA, McGreal MJ, Thiel EC, Fine S, Erlichman C. Patients' willingness to enter clinical trials: measuring the association with perceived benefit and preference for decision participation. Soc Sci Med. 1991;32:35-42.
https://doi.org/10.1016/0277-9536(91)90124-U
Cartmell KB, Bonilha HS, Matson T, Bryant DC, Zapka JG, Bentz TA, et al. Patient participation in cancer clinical trials: A pilot test of lay navigation. Contemp Clin Trials Commun. 2016;3:86-93.
https://doi.org/10.1016/j.conctc.2016.04.005
Lara PNJ, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol. 2001;19:1728-33.
https://doi.org/10.1200/JCO.2001.19.6.1728
Tan CHH, Wilson S, McConigley R. Experiences of cancer patients in a patient navigation program: a qualitative systematic review. JBI Database Syst Rev Implement Rep. 2015;13:136-68.
https://doi.org/10.11124/jbisrir-2015-1588
Joseph RR. Viewpoints and concerns of a clinical trial participant. Cancer. 1994;74 9 Suppl:2692-3.
https://doi.org/10.1002/1097-0142(19941101)74:9+<2692::AID-CNCR2820741818>3.0.CO;2-M
Dal-ré R. ¿Los pacientes deben recibir una remuneración económica por su participación en ensayos clínicos terapéuticos? Med Clin (Barc) [Internet]. 2006;127:59-65. Disponible en: http://dx.doi.org/10.1157/13089991.
https://doi.org/10.1157/13089991
Halpern SD, Karlawish JHT, Casarett D, Berlin JA, Asch DA. Empirical assessment of whether moderate payments are undue or unjust inducements for participation in clinical trials. Arch Intern Med. 2004;164:801-3.
https://doi.org/10.1001/archinte.164.7.801
Bentley JP, Thacker PG. The influence of risk and monetary payment on the research participation decision making process. J Med Ethics. 2004;30:293-8.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
